- Trials with a EudraCT protocol (355)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
355 result(s) found for: Group work.
Displaying page 1 of 18.
EudraCT Number: 2021-000874-28 | Sponsor Protocol Number: 1 | Start Date*: 2021-07-08 |
Sponsor Name:Gyn.Dept, Aabenraa Hospital, Sygehus Sønderjylland | ||
Full Title: Effect of 24 mg dexamethasone preoperatively on surgical stress, pain and recovery in robotic-assisted laparoscopic hysterectomy | ||
Medical condition: robotic- assisted hysterectomy | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003188-90 | Sponsor Protocol Number: ENFORCE-PLUS | Start Date*: 2021-07-01 | |||||||||||
Sponsor Name:CHIP - Rigshospitalet - University of Copenhagen | |||||||||||||
Full Title: A Phase IV Vaccine Study under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE PLUS) | |||||||||||||
Medical condition: The primary objective of the study is to assess if the SARS-CoV-2 vaccine Johnson & Johnson/Janssen results in change in number and activation of platelets and anti-PF4 level. As well as to compare... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002650-67 | Sponsor Protocol Number: IBERepic/2018 | Start Date*: 2018-11-15 |
Sponsor Name:Ibermutuamur (Mutua Colaboradora con la Seguridad Social nº 274) | ||
Full Title: Comparison of the efficacy of autologous platelet rich plasma injections, and extracorporeal shock wave therapy, in the treatment of work –related lateral epicondylitis. | ||
Medical condition: The epicondylitis is an overuse injury, in most cases, is a self-limited course and responds well to conservative treatment. Its etiology is degenerative and is related to a repetitive overuse and ... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004253-11 | Sponsor Protocol Number: 1237.15 | Start Date*: 2012-01-11 | |||||||||||
Sponsor Name:Boehringer Ingelheim Finland Ky | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, parallel group study to determine the effect of 12 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5/5 µg, 5/5 µ... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) DE (Completed) HU (Completed) ES (Completed) IE (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002871-18 | Sponsor Protocol Number: A-92-52030-166 | Start Date*: 2006-02-09 |
Sponsor Name:IPSEN PHARMA, S.A. | ||
Full Title: Phase II, open, single group,multicentre study to evaluate the efficacy and safety of Somatuline Autogel® (120 mg) administered every 4 weeks by deep subcutaneous injection in the tumour´s growth s... | ||
Medical condition: Patients with progressive neuroendocrine tumours who are not eligible to be treated with either surgery or chemotherapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-002831-16 | Sponsor Protocol Number: TUD-TEMANX-065 | Start Date*: 2015-10-20 | |||||||||||
Sponsor Name:Technische Universität Dresden | |||||||||||||
Full Title: Validation of a test system for development of medications for alcoholism | |||||||||||||
Medical condition: male and female volunteers aged 25-55 years with moderate risky alcohol consumption of at least 41 g/day (men) or 31 g/day (women), according to European Medicines Agency (EMA, 2010) this is at lea... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001440-26 | Sponsor Protocol Number: PrevenCOVID-19 | Start Date*: 2020-04-19 |
Sponsor Name:Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI) | ||
Full Title: Pilot, double-blind clinical trial to evaluate the efficacy and safety of pre-exposure use of hydroxychloroquine versus placebo in the prevention of SARS-CoV-2 (COVID-19) infection in healthcare pe... | ||
Medical condition: Prevention of SARS-CoV-2 (COVID-19) infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-006003-42 | Sponsor Protocol Number: ENFORCE | Start Date*: 2020-12-30 | |||||||||||
Sponsor Name:CHIP - Rigshospitalet - University of Copenhagen | |||||||||||||
Full Title: National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE) | |||||||||||||
Medical condition: The aim is to study primarily effectiveness as well as safety of citizens being vaccinated with one of the SARS-CoV2 vaccines being applied in the Danish COVID-19 vaccine programme. Whereas ongoi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002509-22 | Sponsor Protocol Number: ID2687 | Start Date*: 2019-11-21 | |||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
Full Title: Impact of totally transdermal sedation in the weaning from remifentanil infusion among critically ill patients undergoing mechanical ventilation: a pilot randomized-controlled Study | |||||||||||||
Medical condition: Invasive mechanical ventilation is a lifesaving intervention among critically ill patients. However, prolonged ventilation is associated with increased morbidity and mortality. Optimal processes fo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000225-36 | Sponsor Protocol Number: hss198 | Start Date*: 2015-05-20 |
Sponsor Name:Helsinki University Hospital | ||
Full Title: PBA (4-phenylbutyrate) in the prevention of intraocular pressure increase caused by glucocorticoids | ||
Medical condition: Intraocular pressure increase caused by glucocorticoid use in genetically predisposed patients | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001316-76 | Sponsor Protocol Number: D9612L00109 | Start Date*: 2006-07-20 |
Sponsor Name:AstraZeneca GmbH | ||
Full Title: A randomized, open, parallel-group, multi-centre, phase IV study to evaluate the efficacy of three different patient management strategies with and without esomeprazole 20 mg during a 3 months main... | ||
Medical condition: Symptoms thought to be gastroesophageal reflux disease (GERD)-related | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003820-58 | Sponsor Protocol Number: D1690C00063 | Start Date*: 2018-02-08 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A double-blind, randomized, parallel group, phase IV study to investigate the effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency and myocardial contractile work in type 2 d... | ||
Medical condition: type 2 diabetes mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-004374-27 | Sponsor Protocol Number: ProPATIent | Start Date*: 2006-10-12 |
Sponsor Name:Philipps-University | ||
Full Title: Prospective, randomized, doubleblind, placebo-controlled trial on changes in acetylcholine receptor antibody titres in autoimmune myasthenia gravis after influenza vaccination (ProPATIent) | ||
Medical condition: Generalized Myasthenia gravis with positive antibodies against Acetylcholine-receptors (ICD10GM2006 G70.0) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-000756-34 | Sponsor Protocol Number: StrepA-negativetonsillitis2019 | Start Date*: 2019-05-29 |
Sponsor Name:Region Jönköping County | ||
Full Title: The SANT - study A randomized controlled clinical trial of Streptococcus group A-negative acute tonsillitis in primary health care - a comparison of phenoxymethylpenicillin and no antibiotic treatm... | ||
Medical condition: J03.0 Pharyngotonsillitis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002592-34 | Sponsor Protocol Number: RID-TB:Dx | Start Date*: 2020-08-28 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Research to Improve the Detection and Treatment of Latent Tuberculosis Infection: Diagnostics (RID-TB:Dx) A randomised controlled trial to evaluate the effectiveness of using the RD-1 based C Tb s... | |||||||||||||
Medical condition: Latent Tuberculosis infection (LTBI) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001952-31 | Sponsor Protocol Number: CRS-03 | Start Date*: 2016-04-14 | |||||||||||
Sponsor Name:Bionorica SE | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial to assess efficacy and safety of the herbal medicinal product Sinupret extract coated tablets in patients ... | |||||||||||||
Medical condition: Chronic rhinosinusitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005601-46 | Sponsor Protocol Number: 000081 | Start Date*: 2013-05-15 | |||||||||||
Sponsor Name:Ferring International Pharmascience Center US, Inc. | |||||||||||||
Full Title: A Multicenter, Open-label, Safety and Tolerability Extension Trial of 5 mg and 10 mg Elobixibat Daily in the Treatment of Chronic Idiopathic Constipation | |||||||||||||
Medical condition: Chronic idiopathic constipation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) SE (Completed) SK (Completed) HU (Completed) CZ (Completed) GB (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002968-27 | Sponsor Protocol Number: INTERMEDIATE-01 | Start Date*: 2020-02-18 | |||||||||||
Sponsor Name:Centre François Baclesse | |||||||||||||
Full Title: Multicentric phase III trial comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine administration (3.7 GBq I131 after rhTSH) versus decision o... | |||||||||||||
Medical condition: Differentiated thyroid cancer - subgroup of patients with intermediate risk of postoperative residual disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001386-16 | Sponsor Protocol Number: TUD-TEMACA-069 | Start Date*: 2019-07-16 |
Sponsor Name:Technische Universität Dresden | ||
Full Title: Investigation of the efficacy of acamprosate and calcium in comparison to placebo as validation of a behavioural test for alcohol dependence (TEMACA) | ||
Medical condition: persons with disturbance in alcohol use according DSM5 which do not want to change their alcohol consumption | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-003607-30 | Sponsor Protocol Number: ZLB04_009CR | Start Date*: 2015-02-26 | |||||||||||
Sponsor Name:CSL Behring AG | |||||||||||||
Full Title: A Phase III Open-Label, Prospective, Multicenter Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human), IgPro20 in Subjects With Primary Immunode... | |||||||||||||
Medical condition: Primary Immune Deficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
